DEP radiopharmaceutical data supports patent application
Open PDF
| Stock | Starpharma Holdings Ltd (SPL.ASX) |
|---|---|
| Release Time | 2 Jul 2026, 9:20 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Starpharma files patent for radiopharmaceutical platform
Key Points
- DEP® technology shows improved biodistribution
- Patent application filed for radioligand therapy
- Potential for broader oncology applications
Full Summary
Starpharma Holdings Ltd, an innovative biotechnology company, announced the filing of a new patent application supporting its proprietary DEP® technology in radioligand therapy (RLT). The preclinical data indicate that the DEP® platform demonstrates improved biodistribution, with enhanced tumour uptake and retention and reduced off-target accumulation. The findings suggest potential for an improved therapeutic window, with efficient tumour delivery and reduced off-target exposure. The new patent application covers the use of DEP® dendrimer technology in RLT, strengthening Starpharma's platform IP position and supporting its strategy to generate value through the development and partnering of multiple DEP® radiopharmaceutical programs.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In